Quantitative approaches to dopaminergic brain imaging

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 1, 2012, Pages 27-38

  Tatsch, K ^a   Poepperl, G ^b  

^a Municipal Hospital of Karlsruhe Inc   (Germany)

^b KATHARINENHOSPITAL   (Germany)

Author keywords

Dopamine; Neuroimaging; Positron emission tomography; Tomography, emission computed, single photon

Indexed keywords

IODINE 123; RADIOLIGAND; TECHNETIUM 99M;

AUTOMATION; BRAIN SIZE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOPAMINERGIC SYSTEM; HUMAN; IMAGE ANALYSIS; NEUROIMAGING; NEUROPSYCHIATRY; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VOXEL BASED MORPHOMETRY;

BRAIN; DOPAMINE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84861309334     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
2. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992 Neurology 2001;57:S34-8.
3. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009;24:500-8.
4. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102. (Pubitemid 29161211)
5. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70. (Pubitemid 34279780)
6. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-82. (Pubitemid 29140031)
7. Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx 2004;1:243-54. (Pubitemid 46613776)
8. Nikolaus S, Antke C, Kley K, Poeppel TD, Hautzel H, Schmidt D et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007;18:439-72. (Pubitemid 351184054)
9. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol 2001;86:237-47.
10. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 2005;46:936-44.
11. Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl Med 2010;51:1331-4.
12. Seibyl JP, Russell D, Jennings D, Marek K. The molecular basis of dopaminerigc brain imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012;56:4-16.
13. Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012;56:68-82.
14. Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging 2011;38:764-73.
15. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-8. (Pubitemid 14235666)
16. Wagner HN, Jr., Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T et al. Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:1264-6. (Pubitemid 13001277)
17. Kung HF, Alavi A, Chang W, Kung MP, Keyes JW, Jr., Velchik MG et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990;31:573-9. (Pubitemid 20179695)
18. Costa DC, Verhoeff NP, Cullum ID, EH PJ, Syed GM, Barrett J et al. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans. Eur J Nucl Med 1990;16:813-6. (Pubitemid 20318341)
19. Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12:699-707.
20. Verhoeff NP, Brucke T, Podreka I, Bobeldijk M, Angelberger P, Van Royen EA. Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl Med Commun 1991;12:687-97.
21. Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect 1993;94:137-46. (Pubitemid 23345522)
22. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 1993,90:11965-9. (Pubitemid 24008761)
23. Kuikka JT, Bergstrom KA, Vanninen E, Laulumaa V, Hartikainen P, Lansimies E. Initial experience with single-photon emission tomography using iodine-123-labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane in human brain. Eur J Nucl Med 1993;20:783-6. (Pubitemid 23315294)
24. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I]beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-94.
25. Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 1993;34:2076-84. (Pubitemid 24002946)
26. Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002;29:1623-9.
27. Katzenschlager R, Costa D, Gerschlager W, O'Sullivan J, Zijlmans J, Gacinovic S et al. [123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. Ann Neurol 2003;53:489-96. (Pubitemid 36373260)
28. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
29. Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000;41:220-7. (Pubitemid 30091339)
30. Morton RJ, Guy MJ, Clauss R, Hinton PJ, Marshall CA, Clarke EA. Comparison of different methods of DatSCAN quantification. Nucl Med Commun 2005;26:1139-46. (Pubitemid 41677606)
31. Morton RJ, Guy MJ, Marshall CA, Clarke EA, Hinton PJ. Variation of DaTSCAN quantification between different gamma camera types. Nucl Med Commun 2005;26:1131-7. (Pubitemid 41677605)
32. Fleming JS, Bolt L, Stratford JS, Kemp PM. The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol 2004;49:N227-34.
33. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 2006;33:1491-9. (Pubitemid 44885416)
34. Habraken JB, Booij J, Slomka P, Sokole EB, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999;40:1091-7. (Pubitemid 29315496)
35. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46:1109-18. (Pubitemid 43741072)
36. Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun 2005;26:39-43. (Pubitemid 40189623)
37. la Fougere C, Popperl G, Levin J, Wangler B, Boning G, Uebleis C et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 2011;51:581-7.
38. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging 2007;34:1240-53. (Pubitemid 47290660)
39. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med 2007;48.857-64.
40. Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur J Nucl Med Mol Imaging 2006;33:1062-72. (Pubitemid 44215672)
41. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)1 SPECT. J Nucl Med 2003;44:1184-93. (Pubitemid 39663393)
42. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998;39:904-11. (Pubitemid 28216748)
43. Koole M, Laere KV, de Walle RV, Vandenberghe S, Bouwens L, Lemahieu I et al. MRI guided segmentation and quantification of SPECT images of the basal ganglia: a phantom study. Comput Med Imaging Graph 2001;25:165-72. (Pubitemid 32011244)
44. Yin D, Valles FE, Fiandaca MS, Forsayeth J, Larson P, Starr P et al. Striatal volume differences between non-human and human primates. J Neurosci Methods 2009;176:200-5.
45. Rousset OG, Collins DL, Rahmim A, Wong DF. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J Nucl Med 2008;49:1097-106. (Pubitemid 351948018)
46. Rousset OG, Deep P, Kuwabara H, Evans AC, Gjedde AH, Cumming P. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects. Synapse 2000;37:81-9. (Pubitemid 30447938)
47. Ito K, Morrish PK, Rakshi JS, Uema T, Ashburner J, Bailey DL et al. Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;66:754-8. (Pubitemid 29245709)
48. Lucignani G, Gobbo C, Moresco RM, Antonini A, Panzacchi A, Bonaldi L et al. The feasibility of statistical parametric mapping for the analysis of positron emission tomography studies using 1 lC-2-beta-carbomethoxy-3-beta-(4- fluorophenyl)-tropane in patients with movement disorders. Nucl Med Commun 2002;23:1047-55. (Pubitemid 35398977)
49. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003;61:310-5. (Pubitemid 36975957)
50. Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004;127:1332-42. (Pubitemid 38745511)
51. Colloby SJ, O'Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004;23:956-66. (Pubitemid 39446529)
52. Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005;128:1605-12. (Pubitemid 41373679)
53. Kas A, Payoux P, Habert MO, Malek Z, Cointepas Y, El Fakhri G et al. Validation of a standardized normalization template for Statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med 2007;48:1459-67. (Pubitemid 47397396)
54. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238-48.
55. Takada S, Yoshimura M, Shindo H, Saito K, Koizumi K, Utsumi H et al. New semiquantitative assessment of 123I-FP-CIT by an anatomical standardization method. Ann Nucl Med 2006;20:477-84. (Pubitemid 44543866)
56. Bencherif B, Stumpf MJ, Links JM, Frost JJ. Application of MRI-based partial-volume correction to the analysis of PET images of mu-opioid receptors using statistical parametric mapping. J Nucl Med 2004;45:402-8. (Pubitemid 47618612)
57. Buchert R, Berding G, Wilke F, Martin B, von Borczyskowski D, Mester J et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies. Eur J Nucl Med Mol Imaging 2006;33:1073-83. (Pubitemid 44215673)
58. Duarte P, Hustinx R, Couturier O, Smith RJ, Alavi A. Hottest pixel analysis: useful value or statistical artifact? J Nucl Med 1999;40:292P.
59. Acton PD, Mozley PD, Kung HF. Logistic discriminant parametric mapping: a novel method for the pixel-based differential diagnosis of Parkinson's disease. Eur J Nucl Med 1999;26:1413-23. (Pubitemid 29515602)
60. Hamilton D, List A, Butler T, Hogg S, Cawley M. Discrimination between parkinsonian syndrome and essential tremor using artificial neural network classification of quantified DaTSCAN data. Nucl Med Commun 2006;27:939-44. (Pubitemid 44706888)
61. Acton PD, Newberg A. Artificial neural network classifier for the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 2006;51:3057-667
62. Ichise M, Meyer JH, Yonekura Y. An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001;42:755-63. (Pubitemid 32453465)
63. Koch W, Hamann C, Welsch J, Popperl G, Radau PE, Tatsch K. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? J Nucl Med 2005;46:1804-11. (Pubitemid 46196641)
64. Koch W, Suessmair C, Tatsch K, Popperl G. Iterative reconstruction or filtered backprojection for semi-quantitative assessment of dopamine D receptor SPECT studies? Eur J Nucl Med Mol Imaging 2011;38:1095-103.
65. Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging 2010;37:23-35.
66. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010;37:443-50.
67. Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European (123)I-FPCIT SPECT database. Eur J Nucl Med Mol Imaging 2012;39:188-97.
68. Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C et al. Calibration of gamma camera systems for a multicentre European (1)(2)(3)I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging 2011;38:1529-40.
69. Meyer PT, Sattler B, Lincke T, Seese A, Sabri O. Investigating dopaminergic neurotransmission with 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003;44.839-45.
70. Koch W, Hornung J, Hamann C, Popperl G, Tatsch K. Equipment-independent reference values for dopamine transporter imaging with 123I-FP-CIT. Nuklearmedizin 2007;46:107-11. (Pubitemid 46877681)
71. Koch W, Radau PE, Munzing W, Tatsch K. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur J Nucl Med Mol Imaging 2006;33:495-502.
72. Crespo C, Gallego J, Cot A, Falcon C, Bullich S, Pareto D et al. Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. Eur J Nucl Med Mol Imaging 2008;35:1334-42.
73. Tatsch K. Standardisation and harmonisation boost the credibility of nuclear medicine procedures. Eur J Nucl Med Mol Imaging 2012;39:186-7.